Clinical Trials Browser

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

Malignant Female Reproductive System Neoplasm

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasms

Stomach Neoplasms

Breast Neoplasms

Breast Neoplasms

Neoplasm Metastasis

Ependymoma, Meningioma, Neuroma, Acoustic, Neurofibromatosis 2

Brain Neoplasms, Breast Neoplasms

Glioblastoma

Carcinoma, Lobular

Breast Cancer With Brain Metastasis

Breast Neoplasms

Breast Neoplasms

Neoplasm Metastasis

Carcinoma, Carcinoma, Pancreatic Ductal

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Salivary Gland Neoplasms, Cholangiocarcinoma

Brain Neoplasms

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms

Breast Neoplasms, Neoplasm Metastasis

Prostatic Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

Colorectal Neoplasms

Brain Neoplasms, Breast Neoplasms

HER2-positive Breast Cancer

Breast Neoplasms

Brain Neoplasms

Advanced Breast Cancer

Breast Neoplasms

Breast Neoplasms, Neoplasms

Breast Neoplasms, Neoplasm Metastasis

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Clinical Trials

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)

I-SPY

Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers

Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer

HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer

GERTRUDE

INTUITT-NF2

Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling

INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers

THUNDER

Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib

DIANER

Neratinib and Trastuzumab Biosimilar in Patients with HER2 Mutated Advanced Solid Cancers

Using Tumor Models to Determine Treatments

SPRING

CVL009-C2001

Nilatinib Maleate Tablets Combined With Capecitabine in the Treatment of HER2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastases

SUMMIT

HER2-Signal

Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer

A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With Neratinib

NEREA

Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status

NeraBrain

Neratinib Dose Escalation Regimen for HER2 Positive Early Breast Cancer

Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer

TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)

plasmaMATCH

NEFERTT

Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer

Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer

Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer

Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer